Brian Concannon
CEO, Haemonetics Corp.
Brian Concannon had an awfully busy year presiding over Haemonetics Corp. (NYSE:HAE) in 2010.
One of the biggest names in blood management completed four acquisitions, including its March buyout of healthcare information technology firm Global Med Technologies Inc. for $60 million.
That deal completed the Braintree, Mass.-based company’s five-year transformation from a medical device company into “The blood management company,” as Haemonetics would have it. Look for the firm to continue to grow its business in the coming years, as it integrates its bolt-on acquisitions and attempts to automate the blood business.
MassDevice New Year’s Special P/review
- P/review: Introduction
- P/review: Paul LaViolette
- P/review: Stephen Ubl
- P/review: David Lucchino
- P/review: Euan Thomson
- P/review: Brian DeChristopher
- P/review: Christopher Delporte
- P/review: Don Hardison
- P/review: Brent Hudson
- P/review: Hamid Tatabaie
- P/review: Patrick Dentinger
- P/review: Nancy Briefs
- P/review: Brian Concannon
- P/review: Ryan Howard
- P/review: Ed Berger
- P/review: Top stories of 2010
The company is also losing two key players with the retirement of former CEO Brad Nutter from the board and of corporate affairs VP Lisa Lopez (ending what will be a 23-year run with the company this spring).
With all that and more on his plate, Concannon was kind enough to give us his thoughts on the coming year for the medical device industry.
“I believe we will continue to see a rebound in the economy, albeit slower than I think most predict,” he said. “And I think we will see M&A activity increase with the amount of money that is sitting on the sidelines in many of the larger corporations.”
